Escitalopram/QT Prolonging Agents Interactions
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Both of your medicines may affect your heart's rhythm.
What might happen:
Taking two or more medicines that can affect your heart rhythm may increase your risk of irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to perform an electrocardiogram (ECG) on you to check your heart's rhythm. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
- 1.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
- 2.Lexapro (escitalopram oxalate) US prescribing information. Forest Pharmaceuticals Inc. September, 2021.
- 3.USFood and Drug Administration. FDA Drug Safety Communication: Revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm297391.htm March 28, 2012.
- 4.Health Canada. Antidepressant Cipralex (escitalopram): Updated information regarding dose-related heart risk. Available at: http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/1367 4a-eng.php May 7, 2012.
- 5.Cipralex (escitalopram oxalate) Canadian prescribing information. Lundbeck August 13, 2012.
- 6.Cipralex (escitalopram oxalate) UK summary of product characteristics. Lunbeck Limited June 25, 2020.
- 7.USDepartment of Health and Human Services Food and Drug Administration. ICH E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. Available at: https://www.fda.gov/media/71372/download October, 2005.
- 8.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.
CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.